Author:
С. Ю. Матвєєва ,Т. Р. Уманець
Abstract
The article presents the results of the study on the effectiveness and safety of sublingual allergen-specific immunotherapy in children at the age from 4 to 17 years old with spring polinosis and birch-pollen allergy syndrome, which were assessed using visual analogue and combination scales, provocative tests and the results of component resolved diagnosis.
Reference11 articles.
1. Brożek J. L., Bousquet J., Agache I. et. al. Allergic Rhinitis and its Impact on Asthma (ARIA). The Journal of Allergy and Clinical Immunology, 2017 Oct, Vol. 140, Issue 4, P. 950–958.
2. Barr G., Al-Reefy H, Fox A.T., Hopkins C. Allergic rhinitis in children. BMJ, 2014 July; 349.
3. Penagos M., Eifan A. O, Durham S.R., Scadding G. W. Duration of Allergen Immunotherapy for Long- Term Efficacy in Allergic Rhinoconjunctivitis. Current Treatment Options in Allergy, 2018 Aug, Vol. 5(3), P. 275–290.
4. Treatments for Seasonal Allergic Rhinitis. Source: https://effectivehealthcare.ahrq.gov/topics/asthma-immunotherapy-2010/research-protocol.
5. Durham S.R., Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol, 2016 Feb, Vol. 139 (2), P. 339-349.